The 5-HT2A receptor binding pattern in the human brain is strongly genetically determined

NeuroImage

Volumn 40, Issue 3, 2008, Pages 1175-1180

  Pinborg, Lars H ^a   Arfan, Haroon ^a   Haugbol, Steven ^a   Kyvik, Kirsten Ohm ^b   Hjelmborg, Jacob v B ^c   Svarer, Claus ^a   Frokjaer, Vibe G ^a   Paulson, Olaf B ^d   Holm, Soren ^a   Knudsen, Gitte M ^a  

^a Copenhagen University Hospital ^*  (Denmark)

^b Institute of Public Health   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Heritability; Positron emission tomography; Receptor; Serotonin 2A; Twins

Indexed keywords

ALTANSERIN; FLUOROALTANSERIN F 18; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; KETANSERIN; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BOLUS INJECTION; CONTINUOUS INFUSION; DIZYGOTIC TWINS; DRUG RECEPTOR BINDING; ENVIRONMENTAL FACTOR; HEREDITY; HERITABILITY; HUMAN; HUMAN EXPERIMENT; MALE; MONOZYGOTIC TWINS; NEUROIMAGING; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; BRAIN; BRAIN LEVEL; GENETICS; ISOTOPE LABELING; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; SCINTISCANNING; TWINS;

ADULT; ANALYSIS OF VARIANCE; BRAIN; BRAIN CHEMISTRY; HUMANS; ISOTOPE LABELING; KETANSERIN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RECEPTOR, SEROTONIN, 5-HT2A; TWINS, DIZYGOTIC; TWINS, MONOZYGOTIC;

EID: 40849097321     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2007.09.019     Document Type: Article

References (37)

1. 2A receptors in normal volunteers: normative data and relationship to physiological and demographic variables. NeuroImage 21 (2004) 1105-1113
2. 2A receptor binding in the caudate nuclei. Int. J. Neuropsychopharmacol. 8 (2005) 1-11
3. Baare W.F., Hulshoff Pol H.E., Boomsma D.I., Posthuma D., de Geus E.J., Schnack H.G., van Haren N.E., van Oel C.J., and Kahn R.S. Quantitative genetic modeling of variation in human brain morphology. Cereb. Cortex 11 (2001) 816-824
4. Bartley A.J., Jones D.W., and Weinberger D.R. Genetic variability of human brain size and cortical gyral patterns. Brain 120 Pt. 2 (1997) 257-269
5. Borg J., Andree B., Soderstrom H., and Farde L. The serotonin system and spiritual experiences. Am. J. Psychiatry 160 (2003) 1965-1969
6. 18F]dopa PET data. J. Neurol. Neurosurg. Psychiatry 57 (1994) 278-284
7. Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., Jones T., and Banati R.B. In-vivo measurement of activated microglia in dementia. Lancet 358 (2001) 461-467
8. DeGrado T.R., Turkington T.G., Williams J.J., Stearns C.W., Hoffman J.M., and Coleman R.E. Performance characteristics of a whole-body PET scanner. J. Nucl. Med. 35 (1994) 1398-1406
9. Farde L., Hall H., Pauli S., and Halldin C. Variability in D2-dopamine receptor density and affinity: a PET study with [11C]raclopride in man. Synapse 20 (1995) 200-208
10. Farde L., Gustavsson J.P., and Jonsson E. D2 dopamine receptors and personality traits [letter]. Nature 385 (1997) 590
11. 2A receptors by agonists and antagonists. Brain Res. Bull. 56 (2001) 441-451
12. 18F]altanserin PET bolus plus infusion approach. Accepted for publication in Eur. J. Nucl. Med. Mol. Imaging.
13. Heiss W.D., and Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur. J. Neurol. 11 (2004) 5-12
14. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q. J. Nucl. Med. 42 (1998) 211-221
15. Lemaire C., Cantineau R., Guillaume M., Plenevaux A., and Christiaens L. Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. J. Nucl. Med. 32 (1991) 2266-2272
16. Lewellen T.K., Kohlmeyer S.G., Miyaoko R.S., Kaplan M.S., Stearns C.W., and Schuber S.F. Investigation of the performance of the general electric ADVANCE positron emission tomograph in 3D mode. IEEETrans Nucl. Sci. 43 (1996) 2199-2206
17. McClearn G.E., Johansson B., Berg S., Pedersen N.L., Ahern F., Petrill S.A., and Plomin R. Substantial genetic influence on cognitive abilities in twins 80 or more years old. Science 276 (1997) 1560-1563
18. 2A receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology (Berl.) 167 (2003) 72-78
19. 2 receptors during depression and self-harm. Am. J. Psychiatry 160 (2003) 90-99
20. 18F]altanserin positron emission tomography. Biol. Psychiatry 55 (2004) 217-224
21. Muller-Gartner H.W., Links J.M., Prince J.L., Bryan R.N., McVeigh E., Leal J.P., Davatzikos C., and Frost J.J. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J. Cereb. Blood Flow Metab. 12 (1992) 571-583
22. Neale M.C., Boker S.M., Xie G., and Maes H.H. Mx: Statistical Modeling, VCU box 900126, Richmond, VA 23298 (2003)
23. 18F]altanserin-PET and the bolus/infusion approach. J. Cereb. Blood Flow Metab. 23 (2003) 985-996
24. Preece M.A., Dalley J.W., Theobald D.E., Robbins T.W., and Reynolds G.P. Region specific changes in forebrain 5-hydroxytryptamine1A and 5-hydroxytryptamine2A receptors in isolation-reared rats: an in vitro autoradiography study. Neuroscience 123 (2004) 725-732
25. Savic I., Persson A., Roland P., Pauli S., Sedvall G., and Widen L. In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet 2 (1988) 863-866
26. 2A receptors after social isolation in mice. Brain Res. 980 (2003) 169-178
27. 18F]altanserin positron emission tomography. Neuropsychopharmacology 29 (2004) 2235-2241
28. Skytthe A., Kyvik K., Holm N.V., Vaupel J.W., and Christensen K. The Danish Twin Registry: 127 birth cohorts of twins. Twin Res. 5 (2002) 352-357
29. Svarer C., Madsen K., Hasselbalch S.G., Pinborg L.H., Haugbol S., Frokjaer V.G., Holm S., Paulson O.B., and Knudsen G.M. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. NeuroImage 24 (20005) 969-979
30. Thompson P.M., Cannon T.D., Narr K.L., van Erp T., Poutanen V.P., Huttunen M., Lonnqvist J., Standertskjold-Nordenstam C.G., Kaprio J., Khaledy M., Dail R., Zoumalan C.I., and Toga A.W. Genetic influences on brain structure. Nat. Neurosci. 4 (2001) 1253-1258
31. 2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr. Res. 31 (1998) 13-17
32. 2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 118 (1995) 689-696
33. 2A receptor changes in schizophrenia. Psychiatry Res. 99 (2000) 123-135
34. Wellman C.L. Dendritic reorganization in pyramidal neurons in medial prefrontal cortex after chronic corticosterone administration. J. Neurobiol. 49 (2001) 245-53.280
35. Willendrup P., Pinborg L.H., Hasselbalch S.G., Adams K.H., Stahr K., Knudsen G.M., and Svarer C. Assessment of the precision in co-registration of structural MR-images and PET-images with localized binding. In: Iida H., Shah N.J., Hayashi T., and Watabe H. (Eds). International Congress Series (2004) 275-280
36. Wood G.E., Young L.T., Reagan L.P., Chen B., and McEwen B.S. Stress-induced structural remodeling in hippocampus: prevention by lithium treatment. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 3973-3978
37. Wright I.C., Sham P., Murray R.M., Weinberger D.R., and Bullmore E.T. Genetic contributions to regional variability in human brain structure: methods and preliminary results. NeuroImage 17 (2002) 256-271